IM

Mendus AB (publ)STO Mendus AB Stock Report

Last reporting period 31 Dec, 2023

Updated 01 Nov, 2024

Last price

Market cap $B

0.042

Micro

Exchange

XSTO - Nasdaq STOCKHOLM AB

IMMU.ST Stock Analysis

IM

Uncovered

Mendus AB (publ) is uncovered by Eyestock quantitative analysis.

Market cap $B

0.042

Dividend yield

Shares outstanding

200.17 B

Mendus AB is a biomedical company, which engages in the development of cancer immunotherapies. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2013-04-22. The firm develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The firm develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The firm develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.

View Section: Eyestock Rating